Agreements reached under this partnership
Business Alliance- 1
Use the Company's NxWave™ platform to discover new drugs targeting G protein-coupled receptors (GPCRs) associated with neurological diseases
- 2
Identification of validated, differentiated hit molecules targeting neurological diseases
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The Company is entitled to receive up to US$1.2 billion in milestone payments upon the exercise of options and achievement of development and commercialization milestones, as well as tiered royalties based on global sales. Timing of achievement: Not disclosed.
The impact of this matter on the Company's consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026. Most of the US$10 million milestone payment, approximately ¥1,595 million, is expected to be recognized as revenue in 2026, with the remainder recognized from 2027 onward.
| Item | Details |
|---|---|
| Name of alliance partner | AbbVie Inc. |
| Type of alliance | Business Alliance |
| Details of the alliance | Use the Company's NxWave™ platform to discover new drugs targeting G protein-coupled receptors (GPCRs) associated with neurological diseases, Identification of validated, differentiated hit molecules targeting neurological diseases |
| Numerical targets under the alliance | The Company is entitled to receive up to US$1.2 billion in milestone payments upon the exercise of options and achievement of development and commercialization milestones, as well as tiered royalties based on global sales. Timing of achievement: Not disclosed. |
| Contract Date | 2022 |
| Alliance start date | 2022 |
| Impact on Business Performance | The impact of this matter on the Company's consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026. Most of the US$10 million milestone payment, approximately ¥1,595 million, is expected to be recognized as revenue in 2026, with the remainder recognized from 2027 onward. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Achievement of a milestone related to the identification of validated, differentiated hit molecules targeting neurological diseases.